Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)
Shots:
- The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks.
- P-III DELOS study results: 50% reduction in annual rates of forced vital capacity; treatment effect remained 6 yrs.; reduction in risk of important patient-relevant outcomes including bronchopulmonary AEs and hospitalizations; reductions in the rate of both inspiratory and expiratory respiratory function loss
- Idebenone is a benzoquinone and a cofactor for the enzyme NAD(P)H H quinone oxidoreductase (NQO1) approved for Leber's hereditary optic neuropathy (LHON) in the EU including n- Norway- Iceland- Liechtenstein- Israel and Serbia
Ref: Santhera Pharmaceuticals | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com